VANCOUVER, April 19, 2018 /CNW/ - The following issues have been halted by IIROC: Company: Vela Minerals Ltd. TSX-Venture Symbol: VLA Reason: At the Request of the Company Pending News Halt Time (ET): 09:34 IIROC can make a decision to impose a temporary suspension (halt) of trading in a sec...Read More
Valneva Delivers Strong 2017 Financial Results and Advances Key R&D Programs The Company expects continued double digit product sales growth in 2018 and to invest further in R&D, notably the Lyme and Chikungunya programs Strong sales and EBITDA performance in 2017 Tot...Read More
Valneva Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15 Phase I study (VLA15-101) primary endpoint met No safety concerns associated with VLA15 in any treatment group Encouraging immunogenicity with VLA15 VLA15 is immunoge...Read More
Valneva Initiates Phase I Clinical Study to Evaluate Its Single-Shot Vaccine Candidate against Chikungunya Lyon (France), March 13, 2018 - Valneva SE, a fully integrated commercial stage biotech company focused on developing innovative, lifesaving vaccines, today announced the initiati...Read More
EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS GAITHERSBURG, Md. and LYON, France, February 26, 2018 - Emergent BioSolutions Inc. (NYSE: EBS) and Valneva SE (VLA) today announced the initiation of a Phase 1 clinical tr...Read More
Toronto, Ontario--(Newsfile Corp. - January 11, 2018) - Trading resumes in: Company: Vela Minerals Ltd. TSX-V Symbol: VLA Resumption Time (ET): 08:00 January 12, 2018 IIROC can make a decision...Read More
TORONTO, Jan. 11, 2018 /CNW/ - Trading resumes in: Company: VELA MINERALS LTD. TSX-Venture Symbol: VLA Resumption (ET): 8:00 January 12, 2018 IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are imple...Read More
Valneva to Conduct Investor and Partnering Meetings during the Annual J.P. Morgan Healthcare Conference Lyon (France), December 4, 2017 - Valneva SE today announces that its senior management team will hold investor and partnering meetings in San Francisco during the 36th An...Read More
Valneva Expands its Commercial Operations and Establishes US Infrastructure Lyon (France), November 30, 2017 - Valneva SE, a fully integrated commercial stage biotech company focused on developing innovative, lifesaving vaccines, today announces further expansion of its global com...Read More
Valneva Reports Strong Operational Performance for the First Nine Months of 2017 Strong financial performance for first nine months of 2017 and full year outlook leads to upward revision of EBITDA guidance Total revenues of ?,?79.8 million in the first nine months 2017 compared to ?,?70.7 mill...Read More
Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused on developing innovative, life-saving vaccines, announces today the signing of a $39.6 million one year contract with the US Government's Department of Defense for the supply of its Japan...Read More
Valneva to Present at Jefferies and Stifel 2017 Healthcare Conferences Lyon (France), November 06, 2017 - Valneva SE ("Valneva" or "the Company"), a leading commercial stage biotech company focused on developing innovative lifesaving vaccines, today announces that Thomas Lingelbach, President &...Read More
Valneva Announces Expansion of its Management Board - Strengthening Senior Management for Future Growth Appointment of David Lawrence as Chief Financial Officer (CFO) Appointment of Wolfgang Bender, MD/PhD as Chief Medical Officer (CMO) Lyon (France), August 1, 2017 - Valneva SE ("Valnev...Read More
Valneva and Emergent BioSolutions Join Forces to Develop a Vaccine against the Zika Virus Valneva grants Emergent an exclusive worldwide license for its Zika vaccine technology (ZIKV)Valneva and Emergent will co-develop the vaccine until the release of Phase I data with operational responsibilit...Read More
CALGARY, ALBERTA--(Marketwired - July 25, 2017) - Vela Minerals Ltd. (TSX VENTURE:VLA) ("Vela" or the "Company"), a BC junior mining corporation and Advanced Interactive Gaming Ltd. ("AIG"), a software gaming development company governed by the laws of the Bermuda, are pleased to...Read More
Valneva Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15 Lyme disease is the fastest growing vector-borne infectious disease in the United States, according to the CDC; Currently, there is no vaccine available to protect humans against Lyme disease and VLA15 is...Read More
Vancouver, British Columbia--(Newsfile Corp. - July 18, 2017) - The following issues have been halted by IIROC: Company: Vela Minerals Ltd. TSX-V Symbol: VLA Reason: At the Request of the Company Pending News Halt Time (ET) 14:20 IIROC can make a decision to impose a temporary s...Read More
VANCOUVER, July 18, 2017 /CNW/ - The following issues have been halted by IIROC: Company: Vela Minerals Ltd. TSX-Venture Symbol: VLA Reason: At the Request of the Company Pending News Halt Time (ET): 14:20 IIROC can make a decision to impose a temporary suspension (halt) of trading in a sec...Read More
Valneva Announces Successful Outcome of its AGM and the Appointment of two new Supervisory Board Members; The Company Confirms its Growth Strategy and R&D Outlook Lyon (France), June 30, 2017 - Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused...Read More
Valneva Reports Best Financial Results in the Company's History with its First Year of Positive EBITDA in 2016 The Company expects to continue showing a strong financial performance in 2017 Total revenues and grants of ?,?97.9 million in 2016 (vs ?,?83.3 million in 2015) driven mainly by...Read More